68 RESULTS
COMMENT This is certainly a historic decision by the FDA to approve aducanumab under its accelerated approval pathway. There is no question that at the highest doses tested, it can decrease and remove amyloid from the brain. Much has been written about the fact ...
COMMENT In this very nice work Vogel, Hansson, and colleagues found that in a large number of individuals with underlying AD pathology, four general patterns of tau pathology were observed based on tau-PET scans. These patterns were linked closely to the four ...
COMMENT Like many physicians, physician-scientists, and scientists who work on Alzheimer’s disease, my major goals for our field are to develop treatments that prevent, delay the onset of, or slow the cognitive decline that occurs in AD. In the case of EMERGE and ...
COMMENT This paper shows that, in a very large number of presenilin-1 E280A mutation carriers (Columbian kindred) and age-matched controls, plasma NfL is higher. Statistically, cross-sectional values begin to diverge ~22 years before expected age of onset but ...
COMMENT The compound GV-971, Sodium oligomannate, was recently tested in a people who, based on clinical criteria, had mild to moderate dementia believed to be due to Alzheimer’s disease. Over a 36-week period, participants on GV-971 performed better than placebo ...
COMMENT The finding that this individual with a PS1 E280A mutation did not develop symptoms of cognitive impairment due to AD until her early 70s is very intriguing. The fact that she also has the ApoE3 Christchurch mutation, has very high amyloid deposition, but ...
COMMENT Two interesting papers being published look at the effects of APOE genotype on different aspects of AD, in particular tau pathology and cognitive progression of disease. Bondi and colleagues studied 297 older adults without dementia being followed in ADNI ...
COMMENT Since the interim analysis prompted the decision and they said no safety issues, it implies there was not enough slowing of cognitive decline. It will be difficult to comment in detail until the data are revealed. However, even though this trial was in ...
COMMENT I found both of these papers fascinating. It is convincing that rocking in the young adult humans assessed increased NREM sleep, particularly stage 3, which is where the most slow-wave activity occurs. It also increased slow-wave oscillations and fast ...
COMMENT The new data clearly showed that the anti-Aβ antibody BAN2401 was able to significantly remove amyloid from brain, as quantified by amyloid-PET imaging, in very mildly to mildly impaired individuals with amyloid deposition. The highest dose administered, ...
COMMENT In Wang et al., the authors clearly demonstrate that there are several phenotypes seen in ApoE-4 versus ApoE3-expressing neurons derived from iPSC. They include increased tau phosphorylation, increased Aβ production, and a decrease in GABAergic neurons. ...
COMMENT I had the privilege to get know Ben very well over the last 10 years working with him in many settings. He was unique in many ways. He was obviously a superb scientist, but he was so incredibly imaginative and innovative in the way he approached things. ...
COMMENT In this work, Iaccarino et al. find that specific manipulation of brain gamma activity rapidly over an hour lowers Aβ40 and 42 levels as well as affects microglial gene expression in such a way as to make them more phagocytic. Over time, increasing gamma ...
COMMENT This work from the Herz lab presents an interesting set of findings. The mice they generated express ApoE in the periphery but not in the brain. The main finding is that there is a decrease in the synaptic marker synaptophysin in the neocortex in both ...
COMMENT I’m not an expert on the mathematical modeling done here. While it’s clear that vascular abnormalities can contribute to cognitive decline, I am very concerned about the conclusion drawn from this data, namely that vascular dysregulation is the earliest ...
